Edodekin alfa for Cancer
This study is evaluating whether a combination of two immunotherapy drugs may help treat solid tumors.
See full descriptionAbout the trial for Cancer
Treatment Groups
This trial involves 2 different treatments. Edodekin Alfa is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
About The Treatment
Eligibility
This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Edodekin alfa will improve 2 primary outcomes, 4 secondary outcomes, and 1 other outcome in patients with Cancer. Measurement will happen over the course of Up to 2 cycles of treatment.
Patient Q & A Section
What does edodekin alfa usually treat?
Edodekin alfa is an effective treatment for advanced/metastatic NSCLC/SCLC and metastatic breast cancer. The treatment has also shown to be effective vs other chemotherapy for early-stage malignancies. Adverse events are not anticipated in patients receiving edodekin alfa and are mild to moderate.
What is cancer?
Most individuals at high risk of cancer are unlikely to receive any indication to be tested. This could be due to insufficient knowledge that some tests are indicated, lack of awareness of tests, incorrect beliefs, or lack of willingness due to fear for their test results.
What are the signs of cancer?
There are several signs which can occur before and during the growth phase of cancer, as well as after cancer has started. There are four stages of the cancer, one of which is cancer in its earliest stages; stage I. These signs are not always present at the same time in different people. However, they are very common, since they are easily accessible to a physician. The signs are often present even in asymptomatic cases; such cases do not require treatment unless the person is experiencing problems because of the disease.
What are common treatments for cancer?
Treatments and treatment options may vary according to one's particular cancer type. Treatment for non-small cell lung cancer may include anti-cancer treatment, surgery, and radiation therapy. When it comes to other types of cancers, treatment may include surgery and medications.
Can cancer be cured?
There is no strong evidence to support the assertion that cancer can be cured. It is a difficult disease, for which there unfortunately are no proven curative therapies. Nevertheless, a large number of treatments prolong survival, and may prevent further progression of disease.
What causes cancer?
There is conflicting evidence concerning the causes of cancer and cancer is likely the result of complex interactions between genetics, environment, and other factors. Cancer is the result of genetic mutations in cells that then cause cancerous transformation.
How many people get cancer a year in the United States?
There could be around 80,000 new cases of cancer in the United States if all people got screened every year. The numbers may be higher, depending on data collected in various settings, because most of the surveillance is done only in those most likely to have been at risk. These numbers show that the current detection paradigm needs to be augmented. Although data from the general population are necessary for tracking change over time, information from specific disease settings may be necessary to provide accurate estimates of numbers of new cancers diagnosed.
What is the primary cause of cancer?
It is an important matter for physicians to determine the primary cause of cancer. The primary cancer of more than 90% of patients with cancer is related to environmental exposures. This is especially so in cases of bladder cancer and lung cancer, where exposure to tobacco, and secondarily to asbestos, are known as the major causes of these cancers.
How does edodekin alfa work?
Edodekin alfa is well tolerated, and most patients experienced clinically relevant symptoms of rheumatoid disease alleviation within 3 months. The improvement of disease activity was clinically relevant.
Is edodekin alfa safe for people?
Edodicin alfa is safe for people with CLL/SLL at any stage of the disease, including those in the long term following a successful treatment with ruxolitinib. However, it cannot be used for people with CLL/SLL on the basis of an uncontrolled study. Therefore, further trials with long term follow-up are required.
How serious can cancer be?
There are certain clinical markers, such as CEA, and also pathological examination can indicate how the cancer is progressing. Because most people with cancer can survive cancer, they are not in need of life-sustaining treatment. Most people with a serious illness, however, can survive, but the quality of life is reduced. There is no reason to prolong life when the person is not in good health. It is important to know the importance of the life-sustaining treatment to ensure the quality of life will be improved.
Is edodekin alfa typically used in combination with any other treatments?
Edodekin alfa is occasionally used in combination with other treatments. Inclusion of some other treatments in patients who are eligible for edodekin alfa should be questioned; clinicians should be alert about possible combinations with other agents when considering the use of edodekin alfa.